Small Molecules

15 Feb 2017 Gilead Announces 144-Week Data Evaluating Safety and Efficacy of Genvoya® for Treatment of HIV-1 in Treatment-Naïve Adults
15 Feb 2017 Merck Announces EPOCH Study of Verubecestat for the Treatment of People with Mild to Moderate Alzheimer’s Disease to Stop for Lack of Efficacy
14 Feb 2017 Progenics Pharmaceuticals Announces Initiation of a Phase 1 Clinical Trial of its PSMA-Targeted Therapeutic Candidate 1095 For the Treatment of Metastatic Prostate Cancer
14 Feb 2017 Aviragen Therapeutics Announces Top-Line Results from Phase 2b SPIRITUS Trial of Vapendavir
14 Feb 2017 Janssen Announces Two-drug Combination of Dolutegravir and Rilpivirine Demonstrates Efficacy in Maintaining Viral Suppression in Phase III Clinical Studies
14 Feb 2017 Gilead Presents New Phase 2 Data on Bictegravir, an Investigational Integrase Strand Transfer Inhibitor for the Treatment of HIV
14 Feb 2017 Gilead Announces Findings from New Preclinical Study Evaluating Novel Class of HIV Capsid Inhibitors
14 Feb 2017 Chi-Med Initiates First-In-Human Clinical Trial of Novel FGFR Inhibitor HMPL-453 in Australia
14 Feb 2017 European Commission Approves Once-Daily Olumiant Tablets for Treatment of Adults with Moderate-to-Severe Active Rheumatoid Arthritis
13 Feb 2017 DelMar Pharmaceuticals Announces Dosing of the First Patient in Phase Two Clinical Trial of VAL-083 for MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM)
13 Feb 2017 Zosano Pharma Announces 3.8mg Dose of M207, its Novel Transdermal Therapeutic, Meets Both Co-primary Endpoints in the ZOTRIP Pivotal Efficacy Trial in Migraine
13 Feb 2017 Sage Therapeutics Advances SAGE-217 into Placebo-Controlled Phase 2 Clinical Trial in Major Depressive Disorder
13 Feb 2017 Axovant Sciences Announces Preliminary Results from Interim Analysis of Phase 2 Study Testing Investigational Drug Nelotanserin in Lewy Body Dementia Patients
13 Feb 2017 Acacia Pharma Announces Positive Results From its Fourth and Final Pivotal Trial of BAREMSIS™ for the Rescue Treatment of PONV
10 Feb 2017 Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Study Evaluating JZP-110 for Excessive Sleepiness in Parkinson's Disease
10 Feb 2017 Armetheon Reaches Agreement with FDA to Conduct a 1000 Patient Single Phase 3 Study Prior to NDA Filing for its Novel Oral Anticoagulant Tecarfarin
10 Feb 2017 Ovid Therapeutics Announces First Patient Randomized in the Phase 2 STARS Clinical Trial in Adults with Angelman Syndrome
10 Feb 2017 Neurocrine and BIAL Announce Exclusive North American Licensing Agreement for Opicapone
10 Feb 2017 FDA Approves EMFLAZA™ (deflazacort) Tablets and Oral Suspension for the Treatment of Duchenne Muscular Dystrophy in Patients 5 Years and Older
09 Feb 2017 Neuraltus Pharmaceuticals Provides Enrollment Update on Confirmatory Phase 2 Study of NP001 in ALS
09 Feb 2017 Viking Therapeutics Announces Initial Results from In Vivo Proof-of-Concept Study of VK2809 in Glycogen Storage Disease Ia (GSD Ia)
09 Feb 2017 Acorda Announces Positive Phase 3 Clinical Trial Results for CVT-301
08 Feb 2017 Phase III COMPASS study with Bayer’s Rivaroxaban in Patients with Coronary or Peripheral Artery Disease Shows Overwhelming Efficacy and Meets Primary Endpoint Early
08 Feb 2017 Vyome Biosciences Announces Top-Line Results from Phase 1 Study of VB-1953 for Patients with Facial Acne Vulgaris
06 Feb 2017 ARIAD Announces Submission of Marketing Authorization Application for Brigatinib to the European Medicines Agency

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing